Figure 4, supplementary figure 6 by Kristen Pleil (11084931)

“…</b>a) Systemic E2 synthesis inhibition in high ovarian E2 mice using the aromatase inhibitor letrozole (LET, 10 mg/kg). b) Effects of LET administration on EtOH consumption (N’s = 13 saline VEH, 19 LET). c) Effects of LET administration on elevated plus maze (EPM) % time spent in the open arms (left) or distance traveled (right; N’s = 15 VEH, 14 LET). d) Intra-BNST infusion of LET (1 μg in 200 nl/side) in high E2 status females. e) Effects of intra-BNST LET on EtOH consumption (N’s = 7 VEH, 6 LET). f) Intra-BNST infusion of E2 (20 pg in 200 nl/side) or membrane-impermeable E2 (mE2, 55 pg in 200 nl/side) in low E2 status females. g) Effects of intra-BNST E2 on EtOH consumption (N’s = 8 VEH, 7 E2). h) Effects of intra-BNST mE2 on EtOH consumption (N’s = 12 VEH, 11 mE2). i) Effects of intra-BNST E2 on EPM % time spent in the open arms (left) or distance traveled (right; N’s = 7 VEH, 8 E2). j) Effects of bath application of E2/mE2 on excitatory synaptic transmission in BNSTCRF neurons during slice electrophysiology recordings in low ovarian E2 status female CRF-CrexAi9 reporters. k) Spontaneous excitatory postsynaptic currents (sEPSCs) maximum delta from % baseline during E2/mE2 wash on (E2 nM: 0.01: N = 2, 2 cells; 1: N = 4, 4 cells; 10: N = 5, 7 cells; 100: N = 4, 4 cells; 1000: N = 3, 5 cells; 100 nM mE2: N = 3, 6 cells; l and m are the same cells). l) Time course of BNSTCRF neurons that displayed increase/decrease/no change in sEPSC frequency and amplitude (m) % change from baseline during E2 application and proportion of responding categories (pie charts). …”

Data_Sheet_2_Isolation of High-Purity Extracellular Vesicles by the Combination of Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood Plasma.pd... by Zsófia Onódi (839184)

“…</p><p>Results: The highest band intensities of EV markers Alix, Tsg101 and CD81 were detected by Western blot in F6 of small-scale DGUC (61.5 ± 10.4%; 48.1 ± 5.8%; 41.9 ± 3.8%, respectively) at a density of 1.128–1.174 g/mL, where the presence of vesicles with a mean diameter of 38 ± 2 nm was confirmed by EM and DLS. …”

Data_Sheet_1_Isolation of High-Purity Extracellular Vesicles by the Combination of Iodixanol Density Gradient Ultracentrifugation and Bind-Elute Chromatography From Blood Plasma.pd... by Zsófia Onódi (839184)

“…</p><p>Results: The highest band intensities of EV markers Alix, Tsg101 and CD81 were detected by Western blot in F6 of small-scale DGUC (61.5 ± 10.4%; 48.1 ± 5.8%; 41.9 ± 3.8%, respectively) at a density of 1.128–1.174 g/mL, where the presence of vesicles with a mean diameter of 38 ± 2 nm was confirmed by EM and DLS. …”

Intestinal overexpression of <i>mir-2</i> enhances DA neurodegeneration and is attenuated by AIM-100 when <i>sid-1</i> is wildtype. by Anthony L. Gaeta (13272609)

“…(<b>G</b>) DA neurons were scored for degeneration on days 5 and 7 post-hatching. Values represent mean <u>+</u> S.D. …”

Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Video2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Video1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Video3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.MP4 by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image3_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image4_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Image2_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.TIF by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”

Table1_Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.DOCX by Kai Wang (21246)

“…Finally, we observed downregulation of calcium handling genes and upregulation of NPPB in R403Q vs. WT ECTs. In an HCM phenotype prevention experiment, ECTs were treated for 5-weeks with 250 nM mavacamten or a vehicle control. …”